Close this search box.
Trending now:  
Cardiac Shockwave Therapy: A Promising Treatment for Ischemic Heart Failure
The Evolution of Cardiovascular Magnetic Resonance: A 50-Year Journey
Vessel-Level Coronary Atherosclerotic Plaque Activity Predicts Myocardial Infarction Risk
DanGer Shock: Microaxial Flow Pump versus Standard Care in Infarct-Related Cardiogenic Shock
EuroPCR 2024 Highlights

Content for healthcare professionals only

News |

ESC Heart Failure 2023 Highlights

29 May 2023
ESC HF 2023 Highlights

The European Society of Cardiology (ESC) Heart Failure (HF) congress took place in Prague, Czech Republic from 20-23 May 2023. Here are our top highlights from ESC-HF.

PARAGLIDE-HF (NCT03988634)compared outcomes using sacubitril/valsartan versus valsartan alone in HF with preserved ejection fraction (HFpEF) and worsening HF. Investigators compared proportional change in amino terminal pro–B-type natriuretic peptide (NT-proBNP) between the groups. Patients who received sacubitril/valsartan (n=233) achieved greater reductions in NT-proBNP levels than patients who received valsartan alone (n=233). Sacubitril/valsartan reduced worsening renal function, but increased symptomatic hypotension1.

DAPA MODA (NCT04707352) assessed the effects of dapagliflozin on cardiac remodeling over a period of six months. Investigators enrolled 162 patients with stable chronic HF, regardless of ejection fraction (EF). At 180 day follow-up, investigators noted significant...

Log in to get full access to ESC HF 2023 conference highlights.


Related Topics

Related Articles